ImmunoPrecise Subsidiary Talem Therapeutics Partners with Libera Bio to Uncover Novel Therapies with AI-Powered Antibody Discovery

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) and its independently-operating subsidiary Talem Therapeutics LLC have teamed up with Libera Bio S.L. to tackle the challenge of “undruggable” targets located inside cells – a major unmet medical need estimated to be responsible for 75% of diseases. The collaborative effort between IPA, Talem and Libera Bio will focus on developing treatments for cancer, as many of its disease-causing targets are located deep inside tumor cells.

The intersection of numerous pathways within tumor cells, such as the MAPK pathway or the “Hedgehog Pathway”, can create an ideal environment for tumor growth and a means to evade the immune system. In an effort to slow down tumor growth and inhibit proliferation, small molecules have been developed to disrupt these pathways. Unfortunately, such molecules often lack specificity, resulting in toxic side effects for patients. Talem and Libera Bio are collaborating to utilize nanotechnology to deliver antibodies directly into tumor cells to effectively target these pathways, without the risk of toxicity. This technology promises to revolutionize the treatment of cancer, while providing a safer and more effective treatment option for patients.

Libera Bio’s revolutionary Multifunctional Polymeric Nanocapsules (MPN Technology®) are a groundbreaking way to deliver antibodies directly inside tumor cells, with nanocapsules no bigger than 1/10,000th of a millimeter! This revolutionary technology is designed to protect the antibodies from breakdown in the bloodstream, providing the potential for unprecedented intracellular delivery. Not only can MPNs deliver antibodies, but they can also transport other biologic modalities or combinations of biologics and small molecules, with the potential for passive or active targeting. With this cutting-edge nanotechnology, Libera Bio has taken an important step towards a more effective way to treat cancer.

Talem is leveraging its revolutionary antibody discovery and development expertise, including the LENSai Technology® from BioStrand B.V., to deliver whole antibodies in their natural form. This AI-driven platform optimizes the design of these antibodies, computationally generating and rapidly screening a vast array of diverse candidates against a priority list of targets, including intracellular targets. With Talem, you can trust that you are receiving the highest quality antibodies, quickly and conveniently.

Immunoprecise Antibodies Ltd. and Libera Bio have partnered to develop revolutionary antibodies that can penetrate the cell membrane and target previously undruggable intracellular proteins in cancer treatment. This groundbreaking approach has the potential to revolutionize the way we treat cancer, and the two companies are launching their work by investigating two high-priority intracellular targets. Dr. Jennifer Bath, CEO and President of Immunoprecise Antibodies Ltd., is enthusiastic about the possibilities of this collaboration, calling it the “Holy Grail” of oncology. The goal of the project is to offer the antibodies to larger pharma companies for late-stage development and commercialization.

The team at Libera Bio is thrilled to be teaming up with the IPA Family of Companies and their impressive combination of modern in silico tools and wet lab capabilities. This strategic alliance has the potential to unlock dozens of new avenues for cancer treatment, making it an incredibly exciting time for the future of healthcare.

About Immunoprecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology group that spans across North America and Europe, with subsidiaries such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. under its umbrella. The IPA Family utilizes systems biology and complex artificial intelligence to create its own proprietary technologies for bioplatform-based antibody discovery. This full-continuum therapeutic biologics discovery and development out-licensing provides support to business partners in their journey to uncover innovative biologics that target even the most difficult challenges.

About Libera Bio. S.L.

Libera Bio S.L., a Spanish private company spun off from the University of Santiago de Compostela, is on a mission to revolutionize cancer therapy. Their goal is to make it possible for biologics to pass through the cell membrane and access previously ‘undruggable’ intracellular targets – an ambitious undertaking that can be likened to the quest for the ‘Holy Grail’ in oncology. Through their preclinical studies of antibodies targeting frequent mutations of KRAS, a protein linked to a variety of cancers, Libera Bio is now preparing to conduct clinical trials with the hope of receiving authorization.

Leave a Comment